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The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on
immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive
results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects
of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has
reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to
the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2)
identification of the most promising technologies, (3) testing of high throughput immune signatures and (4)
investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.
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In the past five years, the field of cancer immunotherapy
has been revolutionized by new clinical successes. These
improved outcomes for cancer patients are due to several
years of development of new drugs, preclinical studies and
large scale clinical trials. New immunotherapeutics have
been approved by the FDA, including antibodies that
block immune checkpoint molecules CTLA-4 and PD-1.
Furthermore, very impressive durable responses have
been obtained after adoptive transfer of several types
of cellular populations, including genetically engineered
lymphocytes.
These clinical advances and newly approved thera-
peutics are moving cancer immunotherapy from a niche
approach in limited centers, primarily for melanoma and
renal cancer, to a broadly applicable and effective treat-
ment for many common and deadly cancers. Despite the
success, the current drugs and early data from their vari-
ous combinations do not result in durable responses for
every patient, and they are not without toxicity. There-
fore, a critical roadblock in cancer therapy remains the
identification of patients likely to respond to a given
immunotherapy who could be pre-selected. In addition,* Correspondence: butterfieldl@upmc.edu
1University of Pittsburgh, Pittsburgh, PA, USA
6University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Suite
1.27, Pittsburgh, PA 15213, USA
Full list of author information is available at the end of the article
© 2015 Butterfield et al; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.parameters need to be sought to follow patients during
therapy to identify those that are benefitting before a
clinical response is evident. This is because, contrary to
other treatments, evaluable clinical responses to im-
munotherapy often lag in time due to secondary biologic
activity of tumors due to infiltration by inflammatory
cells [1].
The Society for Immunotherapy of Cancer (SITC) has
been investigating predictive and prognostic biomarkers
of response in cancer immunotherapy for many years.
The Society has focused on immune biomarkers in sev-
eral dedicated workshops [2-4]. Between 2008–2011, the
SITC Taskforce on Immunotherapy Biomarkers devel-
oped a series of recommendations and resources for the
field [5-7]. Since then, the field has progressed further.
New therapeutics are now in common use and tech-
nology has evolved significantly. In addition, a greater
understanding of the tumor microenvironment now ex-
ists, and characterization of tumor infiltrating cell popula-
tions and immune regulatory molecules expressed by both
the tumor and TIL is more commonly performed [8-11].
As a field, we still lack the necessary biomarkers that
identify the patients who are most likely to respond to a
given approach and who will have minimal or acceptable
toxicities, nor do we have defined, standardized and
validated biomarkers to identify the patients who are
responding to a treatment before clinically evidentral. This is an Open Access article distributed under the terms of the Creative
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candidate assays and molecules which seem informative in
a given trial. These include standardized measures for
antigen-specific T cell activation, frequencies of suppres-
sive Treg and MDSC, circulating cytokines and growth
factors, antibody titers, and tumor immune cell infiltrate
characterization. However, most studies only test one or
two readouts, tumor samples are often not available, blood
volumes can be limited, and methods for performing
assays and interpreting the results vary broadly. Further-
more, none of these tests have definitively proven to date
to correlate with clinical outcome across trials.
To address these issues, the SITC Immune Biomarkers
Task Force has reconvened under the continuing leader-
ship of the Steering Committee: Lisa H. Butterfield, Mary
L. Disis, Bernard A. Fox, Samir N. Khleif and Francesco
M. Marincola. In its previous iteration, the Taskforce had
two working groups which individually addressed two gen-
eral areas. Working Group (WG)1, led by Drs. Butterfield
and Disis, focused on issues of standardization and valid-
ation of immune assays. WG2, led by Drs. Marincola and
Peter P. Lee, focused on novel technologies and high
throughput approaches.
The recommendations of the Taskforce, published in
2011 [6] could be summarized as follows:
“Although specific immune parameters and assays are
not yet validated, we recommend following
standardized (accurate, precise, and reproducible)
protocols and use of functional assays for the primary
immunologic readouts of a trial; consideration of
central laboratories for immune monitoring of large,
multi-institutional trials; and standardized testing of
several phenotypic and functional potential potency
assays specific to any cellular product. When
reporting results, the full QA (quality assessment)/QC
(quality control) should be conducted and selected
examples of truly representative raw data and assay
performance characteristics should be included.
Finally, to promote broader analysis of multiple
aspects of immunity, and gather data on variability, we
recommend that in addition to cells and serum, RNA
and DNA samples be banked (under standardized
conditions) for later testing. We also recommend that
sufficient blood be drawn to allow for planned testing
of the primary hypothesis being addressed in the trial,
and that additional baseline and post-treatment blood is
banked for testing novel hypotheses (or generating new
hypotheses) that arise in the field”.Goals of the task force in 2015
For 2015, the SITC Immune Biomarkers Taskforce is
divided into four different WG, reflecting the growthand development of the field of cancer immunotherapy
and the increased understanding of the reach of the
immune system into other areas, like tumor-specific mu-
tations arising during carcinogenesis, the microbiome
and the impact of immunity on responses to tumor sig-
naling pathway modulation with small molecules and
antibodies.
WG1, led by Drs. Magdalena Thurin and Giuseppe
Masucci, is focusing on immunologic monitoring assay
standardization and validation. This group includes
experts from the US National Cancer Institute (NCI),
academia, the US FDA, biotech and pharma. They are
developing roadmaps for standardization and validation
of specific assays that are currently seen as the most
promising, particularly with companion diagnostics as
the goal. They are also examining proficiency panels of
assays, and “integral” and “integrated” (versus explora-
tory) biomarkers in clinical trials, and statistical designs
for biomarker validation.
WG2, led by Dr. Jianda Yuan, is focused on new devel-
opments in biomarker assays and new technologies. This
group also has broad international expertise from aca-
demia and industry, including specialists in specific
technologies like epigenetics, TCR sequencing and flow
cytometry. They are focusing their work on identifying the
most promising new technologies that can be applied to
clinical trials of immunotherapeutic agents, in particular
checkpoint blockade. They are also making recommenda-
tions regarding sample handling and data analysis.
WG3, led by Dr. David Stroncek, is focusing on the
assessment of immune regulation and modulation sys-
tematically. This group has expertise from the NCI, as
well as representatives from international academic and
pharmaceutical companies. They are reviewing the state
of the art of high throughput technologies and recent
studies identifying signatures of immune function, im-
mune response and clinical outcomes in cancer patients.
They are also examining roles for proteomics, metabolo-
mics and the microbiome in understanding immune re-
sponses in patients.
WG4, led by Dr. Sacha Gnjatic, is focusing on predic-
tion of clinical outcome based on baseline measures,
particularly those in the tumor microenvironment. This
WG also includes participants with a broad range of ex-
pertise in both blood and tumor immune assessment,
including faculty from a number of international academic
sites as well as biotech company and pharma representa-
tives. They are examining blood, genetic, transcriptomic,
proteomic and immune infiltrate assessments and sig-
natures to address identification of patients suitable for
different treatment approaches.
Each WG is charged with reviewing the state of the art
for their area, identifying the current scientific and tech-
nical hurdles and making recommendations on how best
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sented in a white paper from each WG, to appear in the
JITC. Another aspect of the Taskforce function is to up-
date the SITC membership and JITC readership with
published brief synopses of new immune monitoring tech-
nologies, as each WG operates in the coming months.
Lastly, members of the Taskforce have received regu-
latory approvals to access banked PBMC and serum
samples from a recently completed clinical trial. This
multi-institution immunotherapy trial for melanoma
tested CTLA-4 blockade +/− the addition of GM-CSF
in a 2-arm trial that included 245 melanoma patients,
which was run with the support of the ECOG-ACRIN
national cooperative group. The initial clinical trial re-
port from F.S. Hodi et al. [12] was recently published.
The blood samples, which are banked at the Immun-
ology Reference Lab for ECOG-ACRIN at the University
of Pittsburgh Cancer Institute, represent an important
resource for immune biomarker testing given the clin-
ical outcomes and toxicity differences. Drs. Butterfield
and Marincola will lead this effort, testing both stan-
dardized cellular immunity and circulating cytokine/
chemokine/growth factor assays (Butterfield/Pittsburgh)
and high throughput genomic and transcriptomic mea-
sures (Marincola/Sidra). This clinical trial project will
also benefit from the discussions of each WG. The re-
sults will also appear in JITC when complete.
Conclusion
Together, the SITC Immune Biomarkers Taskforce
will provide the field of cancer immunotherapy with
continuous status updates on critical immune bio-
markers which are on the path to validation as well
as a roadmap for other established and standardized
biomarkers to become validated. The newest technologies
and high throughput approaches, with their strengths and
weaknesses and sample handling requirements will be
presented. The latest investigations in the tumor micro-
environment and the most informative baseline immune
measures will also be presented. The Taskforce will not
only publish summaries and recommendations but will
also host a day long workshop for open discussion with
the broader field stake holders, planned for the Spring of
2016. Lastly, we will use this Taskforce as the platform
for performing new immune biomarker studies in a
large, multi-institution immunotherapy trial in melanoma.
These banked patient samples provide a critical opportun-
ity for putting the standardized assays and new and high
throughput technologies to the test.
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